These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31410757)

  • 1. Minireview: are SGLT2 inhibitors heart savers in diabetes?
    Grubić Rotkvić P; Cigrovski Berković M; Bulj N; Rotkvić L
    Heart Fail Rev; 2020 Nov; 25(6):899-905. PubMed ID: 31410757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
    Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
    Trujillo JM; Nuffer WA
    Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
    Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
    Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P; Acharya T
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
    Liu H; Sridhar VS; Boulet J; Dharia A; Khan A; Lawler PR; Cherney DZI
    Metabolism; 2022 Jan; 126():154918. PubMed ID: 34699838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiorenal protection with SGLT2 inhibitors (gliflozins) : from EMPA-REG OUTCOME to CANVAS].
    Scheen AJ; Ernest P; Jandrain B
    Rev Med Suisse; 2017 Aug; 13(571):1421-1426. PubMed ID: 28837279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
    Sridhar VS; Rahman HU; Cherney DZI
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():55-68. PubMed ID: 32267075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
    Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD
    J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitors' mechanisms of action in heart failure.
    Grubić Rotkvić P; Cigrovski Berković M; Bulj N; Rotkvić L; Ćelap I
    World J Diabetes; 2020 Jul; 11(7):269-279. PubMed ID: 32843930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.